Related Experiment Video
Updated: Sep 30, 2025
07:44
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
27.6K
Variable predicted pathogenic mechanisms for novel MECP2 variants in RTT patients
Wessam E Sharaf-Eldin1, Mahmoud Y Issa2, Maha S Zaki2
1Medical Molecular Genetics Department, Human Genetics and Genome Research institute, National Research Centre, Cairo, 12311, Egypt. wessam_sharafeldin@yahoo.com.
Journal, Genetic Engineering & Biotechnology
|March 11, 2022
Summary
Computational analysis reveals how specific MECP2 gene mutations impact Rett syndrome, with some reducing DNA binding and others potentially altering protein phosphorylation.
Area of Science:
- Neuroscience and Genetics
- Computational Biology
Background:
- Methyl CpG binding protein 2 (MeCP2) is crucial for mature neuron function.
- Mutations in the MECP2 gene are the primary cause of Rett syndrome (RTT).
Purpose of the Study:
- To analyze the functional consequences of novel and rare MECP2 missense mutations.
- To identify critical factors influencing variant pathogenicity in Rett syndrome.
Main Methods:
- Utilized in silico algorithms to assess missense mutations (D121A, S359Y, P403S, R133H).
- Employed ROC curve analysis to investigate variant pathogenicity factors.
- Applied PREM PDI and GPS v5.0 software for detailed mutation effect analysis.
Main Results:
- Physicochemical properties did not significantly impact variant pathogenicity.
- D121A and R133H mutations were found to reduce MeCP2 DNA binding affinity.
- P403S mutation may alter protein phosphorylation, but protein interaction effects are undocumented.
- The S359Y variant's pathogenic mechanism remained undetermined by the algorithms.
Conclusions:
- The study suggests a computational approach for predicting MECP2 variant effects.
- This model may be particularly useful for variants in the MBD and CTD domains.
